Peer-Reviewed Publications

      SKH-1 mouse skin painting: A short-term assay to evaluate the tumorigenic activity of cigarette smoke condensate

      Roemer, E.; Ottmueller, T. H.; Urban, H. J.; Baillet-Mignard, C.
      Published
      Oct 23, 2009
      DOI
      10.1016/j.toxlet.2009.10.019
      PMID
      19854249
      Link to publication
      Topic
      Summary

      The hairless mouse strain SKH-1 was investigated in a short-term assay to assess the tumorigenic activity of mainstream cigarette smoke condensate (CSC). The design chosen was the two-stage dermal tumorigenicity assay (skin painting), with tumor initiation using a single dermal application of the carcinogen/mutagen dimethylbenz(a)anthracene applied to the back at a non-tumorigenic dose and tumor promotion by repeated dermal applications of CSC at the same site. The mice reproducibly developed skin tumors at the application site after 15 weeks at a frequency that allowed comparison of the treatment groups. The histopathological examination revealed the benign nature of the tumors (keratotic papillomas). Prolongation of the application period to 25 weeks resulted in the development of malignant tumors (carcinomas), indicating that the benign tumors after 15 weeks can be taken as surrogate endpoints for malignancies progressing after further treatment. After 15 weeks, tumor incidence (the percentage of tumor-bearing mice), tumor multiplicity (the number of tumors per mouse), and tumor-onset (the duration of the application period that resulted in a meaningful tumor incidence) were positively correlated with the initiating and promoting dose. The reproducibility of this assay was at least comparable to that described for other skin painting models in the literature. When the assay system was used to compare CSCs to which different concentrations of benzo(a)pyrene were added, its ability to distinguish these different condensate preparations was comparable to that of other models. The results obtained with the SKH-1 mouse strain suggest its usefulness in the short-term skin painting assay for the comparative investigation of the tumorigenic activity of different CSCs.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.